Archives

The use of antipsychotic drugs for the management of the Behavioral and Psychological Symptoms of Dementia (BPSD) is not an FDA-approved indication, is controversial, and yet continues to be [...]

Before a prescription drug manufacturer can promote a medication for a specific indication they must conduct extensive clinical trials demonstrating safety and effectiveness.  The FDA (Food and [...]

As their dementia progresses, most patients will develop BPSD.  These symptoms may be short-lived, intermittent or persistent.  Psychotic symptoms are the most disturbing for the patient and [...]